# Pfizer Inc.

- Category: Pharmaceuticals & Life Sciences
- Address: 66 Hudson Boulevard East, New York, NY 10001-2192
- Phone: +1 212-733-2323
- Website: https://www.pfizer.com
- Last updated: 2026-11-15
- Source page: https://professionalbusinessdirectory.com/places/pfizer-inc/

## Profile

Pfizer Inc. is a research-based biopharmaceutical company that discovers, develops, manufactures and sells medicines and vaccines worldwide. Its global headquarters and principal executive offices are at 66 Hudson Boulevard East in New York City. The company is incorporated in Delaware and its common stock trades on the New York Stock Exchange as PFE.

## Identity

- Legal name (10-K cover): Pfizer Inc.

- Ticker and exchange: PFE, New York Stock Exchange

- State of incorporation: Delaware (incorporated June 2, 1942)

- SEC CIK: 0000078003 (SEC commission file number 1-3619)

- Fiscal year end: December 31

- Category: Pharmaceuticals and life sciences; biopharmaceutical company

## Business structure and 2025 revenue

The Form 10-K for the year ended December 31, 2025 reports total revenues of $62,579 million, of which $37,078 million came from the United States. Pfizer manages commercial operations through three operating segments: Biopharma, PC1 (a contract development and manufacturing organization) and Pfizer Ignite (R&D services for selected biotech companies). The 10-K states that Pfizer decided in 2025 to discontinue Pfizer Ignite and that Biopharma is the only reportable segment.
For 2026 the 10-K groups Biopharma products into Primary Care, Specialty Care, Oncology, and Hospital and Biosimilars. Products it names include Eliquis, Nurtec ODT, the Prevnar family, Comirnaty and Paxlovid in Primary Care; Xeljanz, Cibinqo and the Vyndaqel family in Specialty Care; Ibrance, Xtandi, Padcev and Adcetris in Oncology; and Inflectra and Retacrit among biosimilars. Comirnaty revenue was $4,367 million and Paxlovid revenue was $2,362 million in 2025. The 10-K also cites the company’s November 2025 acquisition of Metsera.

## Workforce and facilities

As of December 31, 2025, Pfizer employed approximately 75,000 people worldwide. The 10-K says the company supplies medicines and vaccines to approximately 200 countries and territories, owned or leased 245 properties totaling about 36 million square feet, and had 36 manufacturing plants under Pfizer Global Supply.

## How to verify this company yourself

- [SEC EDGAR filer page for Pfizer Inc. (CIK 0000078003)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000078003&type=10-K)

- [Form 10-K for fiscal year 2025 (cover page, Item 1 business, Item 2 properties)](https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/pfe-20251231.htm)

- [Pfizer official contact page (address, customer service line, adverse-effect reporting, media contact)](https://www.pfizer.com/contact)

- [Pfizer investor relations site](https://investors.pfizer.com) (the domain Pfizer names in its own press releases)

## Location and contact

- Global headquarters and principal executive offices (10-K cover; same on pfizer.com/contact): 66 Hudson Boulevard East, New York, NY 10001-2192

- Corporate telephone (10-K cover): [+1 212-733-2323](tel:+12127332323)

- Customer service and product inquiries (pfizer.com/contact; Monday to Friday, 9:00 a.m. to 7:00 p.m. EST): [+1 800-879-3477](tel:+18008793477)

- Website: [pfizer.com](https://www.pfizer.com)

Last verified: November 6, 2026. Sources: Pfizer Form 10-K for fiscal 2025 (filed February 26, 2026); SEC EDGAR submissions record for CIK 0000078003; pfizer.com/contact; Pfizer press release of December 17, 2024 (investor site domain).
Directory listing. Not investment advice, not a product review, and not medical advice. Product names are those published in the company’s 10-K.
Listing type: Editorial. Not claimed by the company. Not sponsored. [Send a correction](https://professionalbusinessdirectory.com/contact/).

---
Published by Professional Business Directory (https://professionalbusinessdirectory.com/). Editorial process: https://professionalbusinessdirectory.com/editorial-process/
